Different properties of ACPA and IgM-RF derived from a large dataset: Further evidence of two distinct autoantibody systems

Arthritis Research and Therapy

Volumn 11, Issue 3, 2009, Pages

  Ursum, Jennie ^a   Bos, Wouter H ^a   van de Stadt, Rob J ^a   Dijkmans, Ben A C ^b   van Schaardenburg, Dirkjan ^a,b  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; POLYARTHRITIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEROCONVERSION; SPONDYLOARTHROPATHY; AGE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; FACTUAL DATABASE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RHEUMATOID FACTOR;

EID: 67650733181     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2704     Document Type: Article

References (23)

1. Nishimura K Sugiyama D Kogata Y Tsuji G Nakazawa T Kawano S Saigo K Morinobu A Koshiba M Kuntz KM Kamae I Kumagai S Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis Ann Intern Med 2007, 146:797-808. 17548411
2. Kastbom A Strandberg G Lindroos A Skogh T Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) Ann Rheum Dis 2004, 63:1085-1089. 1755123 15308517 10.1136/ard.2003.016808
3. Avouac J Gossec L Dougados M Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review Ann Rheum Dis 2006, 65:845-851. 10.1136/ ard.2006.051391 16606649
4. Schellekens GA de Jong BA Hoogen van den FH Putte van de LB van Venrooij WJ Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies J Clin Invest 1998, 101:273-281. 508564 9421490 10.1172/JCI1316
5. Nell-Duxneuner V Machold K Stamm T Eberl G Heinzl H Hoefler E Smolen JS Steiner G Autoantibody profiling in patients with very early rheumatoid arthritis - a follow-up study Ann Rheum Dis 2009. 19153104
6. Rönnelid J Wick MC Lampa J Lindblad S Nordmark B Klareskog L van Vollenhoven RF Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression Ann Rheum Dis 2005, 64:1744-1749. 1755292 15843452 10.1136/ard.2004.033571
7. Bobbio-Pallavicini F Caporali R Alpini C Moratti R Montecucco C Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients Ann N Y Acad Sci 2007, 1109:287-295. 10.1196/annals.1398.034 17785317
8. Knijff-Dutmer E Drossaers-Bakker W Verhoeven A Sluijs Veer van der G Boers M Linden van der S Laar van de M Rheumatoid factor measured by fluoroimmunoassay: A responsive measure of rheumatoid arthritis disease activity that is associated with joint damage Ann Rheum Dis 2002, 61:603-607. 1754168 12079900 10.1136/ard.61.7.603
9. Bos WH Bartelds GM Wolbink GJ de Koning MH Stadt van de RJ van Schaardenburg D Dijkmans BA Nurmohamed MT Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis J Rheumatol 2008, 35:1972-1977. 18785316
10. van Schaardenburg D Lagaay AM Otten HG Breedveld FC The relation between class-specific serum rheumatoid factors and age in the general population Br J Rheumatol 1993, 32:546-549. 10.1093/rheumatology/ 32.7.546 8339123
11. Palosuo T Tilvis R Strandberg T Aho K Filaggrin related antibodies among the aged Ann Rheum Dis 2003, 62:261-263. 1754464 12594116 10.1136/ ard.62.3.261
12. Klareskog L Ronnelid J Lundberg K Padyukov L Alfredsson L Immunity to citrullinated proteins in rheumatoid arthritis Annu Rev Immunol 2008, 26:651-675. 10.1146/annurev.immunol.26.021607.090244 18173373
13. Nielen MM van Schaardenburg D Reesink HW Stadt van de RJ Horst-Bruinsma van der IE de Koning MH Habibuw MR Vandenbroucke JP Dijkmans BA Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018 14872479
14. Nielen MM van Schaardenburg D Reesink HW Twisk JW Stadt van de RJ Horst-Bruinsma van der IE de Gast T Habibuw MR Vandenbroucke JP Dijkmans BA Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis Arthritis Rheum 2004, 50:2423-2427. 10.1002/art.20431 15334453
15. Goekoop-Ruiterman YP Vries-Bouwstra JK Kerstens PJ Nielen MM Vos K van Schaardenburg D Speyer I Seys PE Breedveld FC Allaart CF Dijkmans BA DAS-driven therapy versus routine care in patients with recent-onset active Rheumatoid Arthritis Ann Rheum Dis 2009.
16. Atzeni F Sarzi-Puttini P Dell' Acqua D de Portu S Cecchini G Cruini C Carrabba M Meroni PL Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study Arthritis Res Ther 2006, 8:R3. 1526573 16356192 10.1186/ar1851
17. Alessandri C Bombardieri M Papa N Cinquini M Magrini L Tincani A Valesini G Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis 2004, 63:1218-1221. 1754775 15361374 10.1136/ard.2003.014647
18. Bobbio-Pallavicini F Alpini C Caporali R Avalle S Bugatti S Montecucco C Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment Arthritis Res Ther 2004, 6:R264-R272. 416448 15142273 10.1186/ ar1173
19. van Zeben D Hazes JM Zwinderman AH Cats A Voort van der EA Breedveld FC Clinical significance of rheumatoid factors in early rheumatoid arthritis: Results of a follow up study Ann Rheum Dis 1992, 51:1029-1035. 1004831 1417131 10.1136/ard.51.9.1029
20. Vis M Bos WH Wolbink G Voskuyl AE Twisk JW Stadt van de RJ Hamann D Dijkmans BA Lems WF IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis J Rheumatol 2008, 35:425-428. 18322974
21. Dörner T Egerer K Feist E Burmester GR Rheumatoid factor revisited Curr Opin Rheumatol 2004, 16:246-253. 10.1097/00002281-200405000-00013 15103252
22. Lee DM Phillips R Hagan EM Chibnik LB Costenbader KHMM Schur PH Quantifying anti-cyclic citrullinated peptide titres: Clinical utility and association with tobacco exposure in patients with rheumatoid arthritis Ann Rheum Dis 2009, 68:201-208. 10.1136/ard.2007.084509 18390910
23. Matsui T Shimada K Ozawa N Hayakawa H Hagiwara F Nakayama H Sugii S Ozawa Y Tohma S Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis J Rheumatol 2006, 33:2390-2397. 16924694